Metabolic Clearance Rate

"Metabolic Clearance Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.

Descriptor ID	D008657
MeSH Number(s)	E01.370.225.843 E05.200.843 G03.490 G07.690.595 G07.690.725.513
Concept/Terms	Metabolic Clearance Rate Metabolic Clearance Rate Clearance Rate, Metabolic Clearance Rates, Metabolic Metabolic Clearance Rates Rate, Metabolic Clearance Rates, Metabolic Clearance Total Body Clearance Rate Total Body Clearance Rate

Below are MeSH descriptors whose meaning is more general than "Metabolic Clearance Rate".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Diagnostic Techniques and Procedures [E01.370]
Clinical Laboratory Techniques [E01.370.225]
Metabolic Clearance Rate [E01.370.225.843]
Investigative Techniques [E05]
Clinical Laboratory Techniques [E05.200]
Metabolic Clearance Rate [E05.200.843]
Biological Sciences [G]
Metabolism [G03]
Metabolic Clearance Rate [G03.490]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Metabolic Clearance Rate [G07.690.595]
Pharmacokinetics [G07.690.725]
Metabolic Clearance Rate [G07.690.725.513]

Below are MeSH descriptors whose meaning is related to "Metabolic Clearance Rate".

Below are MeSH descriptors whose meaning is more specific than "Metabolic Clearance Rate".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Metabolic Clearance Rate" by people in this website by year, and whether "Metabolic Clearance Rate" was a major or minor topic of these publications.

Bar chart showing 31 publications over 11 distinct years, with a maximum of 7 publications in 2003

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
2003	7	7
2004	4	4
2005	1	1
2006	2	2
2007	3	3
2009	6	6
2010	1	1
2011	1	1
2012	2	2
2017	3	3
2020	1	1

Below are the most recent publications written about "Metabolic Clearance Rate" by people in Profiles.

Siegel SD, Lerman C, Flitter A, Schnoll RA. The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions. Cancer Prev Res (Phila). 2020 03; 13(3):261-272.

View in: PubMed
Zane NR, Reedy MD, Gastonguay MR, Himebauch AS, Ramsey EZ, Topjian AA, Zuppa AF. A Population Pharmacokinetic Analysis to Study the Effect of Therapeutic Hypothermia on Vancomycin Disposition in Children Resuscitated From Cardiac Arrest. Pediatr Crit Care Med. 2017 Jul; 18(7):e290-e297.

View in: PubMed
Albrecht D, Ellis D, Canafax DM, Combs D, Druzgala P, Milner PG, Midei MG. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. Thromb Haemost. 2017 04 03; 117(4):706-717.

View in: PubMed
Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2017 Feb 01; 74(2):180-184.

View in: PubMed
Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ, Haas RH. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res. 2012 Jul; 72(1):43-9.

View in: PubMed
Cushing DJ, Souney PF, Cooper WD, Mosher GL, Adams MP, Machatha S, Zhang B, Kowey PR. Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Clin Exp Pharmacol Physiol. 2012 Jan; 39(1):3-8.

View in: PubMed
Ghobrial GM, Nair AK, Dalyai RT, Jabbour P, Tjoumakaris SI, Dumont AS, Rosenwasser RH, Gonzalez LF. Contrast stasis on noncontrast computed tomography as a predictor of stroke postthrombolysis. Neurosurg Focus. 2011 Jun; 30(6):E13.

View in: PubMed
West KE, Jablonski MR, Warfield B, Cecil KS, James M, Ayers MA, Maida J, Bowen C, Sliney DH, Rollag MD, Hanifin JP, Brainard GC. Blue light from light-emitting diodes elicits a dose-dependent suppression of melatonin in humans. J Appl Physiol. 2011 Mar; 110(3):619-26.

View in: PubMed
Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec; 50(12):1958-63.

View in: PubMed
Gilbert B, Robbins P, Livornese LL. Use of antibacterial agents in renal failure. Infect Dis Clin North Am. 2009 Dec; 23(4):899-924, viii.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement